Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company ...

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT), a commercial-stage biotechnology company with a market capitalization of $428 million specializing in mRNA therapeutics and vaccines, stands at a ...

Arcturus Therapeutics (ARCT) announced the appointment of Moncef Slaoui as chair designate. Slaoui has been serving on the company’s board of ...

Holdings Inc. (NASDAQ: ARCT), a company specializing in mRNA medicines for infectious diseases and rare disorders, has appointed Dr. Moncef Slaoui as its Chair Designate. Dr. Slaoui, a notable figure ...

Arcturus Therapeutics Holdings Inc. stock is down 46% since Sept. 2023 coverage; mRNA sector faces headwinds with public ...

Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company ...

In the assessment of 12-month price targets, analysts unveil insights for Arcturus Therapeutics, presenting an average target ...

BTIG initiated coverage of Arcturus Therapeutics (ARCT) with a Buy rating and $41 price target Arcturus is a commercial-stage biotechnology ...

BTIG Research began coverage on shares of Arcturus Therapeutics (NASDAQ:ARCT – Get Free Report) in a research report issued on Tuesday, MarketBeat reports. The brokerage set a “buy” rating and a ...

This capital helps fund our Energy-as-a-Service offering, allowing us to deploy Arcturus at industrial <a target=_blank href= ...

While the virus hasn’t made a sustained leap into humans, vaccines and treatments are being developed ahead of an outbreak.